aid: bonumtherapeutics

name: Bonumtherapeutics

description: Bonumtherapeutics, operating as Bonum Tx, develops antibody‑controlled therapeutics that deliver potent activity only where needed,
  aiming to improve safety and efficacy across oncology, autoimmunity, metabolic disorders, and pain management. The company leverages a novel
  regulated protein platform validated by Roche’s acquisition of its predecessor Good Therapeutics in 2022, and is advancing preclinical programs
  targeting immune cells and tumor microenvironments.

url: https://raw.githubusercontent.com/api-evangelist/bonumtherapeutics/refs/heads/main/apis.yml

x-type: company

x-source: harvest:secondary-market

x-tier: profiled
x-tier-reason: enrichment pass 2026-10-02 (modular-v1; was harvest)

specificationVersion: '0.20'

created: '2026-10-02'

modified: '2026-10-02'

tags:
- Company
- Biotech
- Therapeutics
- Antibody
- Oncology

maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io

common:
- type: Hosts
  url: hosts/bonumtherapeutics-hosts.yml
- type: Vendors
  url: vendors/bonumtherapeutics-vendors.yml
- type: PrivacyPolicy
  url: https://bonumtx.com/privacy-policy
- type: Newsroom
  url: https://bonumtx.com/news/
- type: DomainSecurity
  url: security/bonumtherapeutics-domain-security.yml
- type: Website
  url: https://bonumtx.com

apis:
- name: Bonum Tx API
  description: API for Bonum Tx platform providing access to therapeutic data and program information.
  humanURL: https://bonumtx.com
  baseURL: null
  properties: []
  aid: bonumtherapeutics:bonum-tx-api

x-coverage:
  state: unreadable
  reason: js-rendered-docs
  detail: Main site loads content via JavaScript, preventing static spec discovery.
  evidence:
  - url: https://bonumtx.com
    status: 200
  checked: '2026-10-02'
x-enrichment:
  date: '2026-10-02'
  status: enriched
  artifacts_added: 5
  pass: modular-v1
  engine: identity=local,contract=local,surfaces=local,docs=local,regulatory=local